Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): Preclinical development and application to the treatment of Parkinson's disease

Experimental Neurology

Volumn 145, Issue 2 I, 1997, Pages 309-321

  Lapchak, Paul A ^a,c   Gash, Don M ^b   Collins, F ^a   Hilt, Dana ^a   Miller, Paul J ^a   Araujo, Dalia M ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c 5665 Walnut Ridge Dr ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; METHAMPHETAMINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NEUROTROPIN;

CENTRAL NERVOUS SYSTEM; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; EXTRACELLULAR MATRIX; IMMUNOCYTOCHEMISTRY; MONOAMINERGIC NERVE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; RHESUS MONKEY;

EID: 0030837593     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6501     Document Type: Review

References (65)

1. Adams, R. D., and M. Victor. 1993. Degenerative diseases of the nervous system. In Principles of Neurology (R. D. Adams, Ed.). McGraw-Hill, New York.
2. Araujo, D. M., D. C. Hilt, P. J. Miller, D. Wen, S. Jiao, and P. A. Lapchak. 1997. RET receptor tyrosine kinase immunoreactivity is altered in GDNF-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways. Neurosci., in press.
3. Arenas, E., M. Trupp, P. Akerud, and C. F. Ibanez. 1995. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15: 1465-1473.
4. Blum, M., and C. S. Weickert. 1995. GDNF mRNA expression in normal postnatal development, aging and in weaver mutant mice. Neurobiol. Aging 16: 925-929.
5. Bowenkamp, K. E., A. F. Hoffman, G. A. Gerhardt, M. A. Henry, P. T. Biddle, and B. J. Hoffer. 1995. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355: 479-489.
6. Bowenkamp, K. E., D. David, P. A. Lapchak, M. A. Henry, A. C. Granholm, B. J. Hoffer, and P. C. Pickford. 1996. Glial cell line-derived neurotrophic factor reverses motor impairment in aged rats. Neurosci. Lett. 211: 81-84.
7. Bowenkamp, K. E., D. David, P. A. Lapchak, M. A. Henry, A. C. Granholm, B. J. Hoffer, and T. J. Mahalik. 1996. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra of the rat. Exp. Brain Res. 111: 1-7.
8. Cass, W. A. 1996. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J. Neurosci. 16: 8132-8139.
9. Gash, D. M., F. Bresjanac, F. Junn, and Z. Zhang. 1994. Trophic mechanisms mediating functional recovery following intrastriatal implantation. In Functional Neuroal Transplantation (S. B. Dunnett and A. Bjorklund, Eds.), pp. 139-156. Raven Press, New York.
10. Gash, D. M., Z. Zhang, W. A. Cass, A. Ovadia, L. Simmerman, D. Russell, D. Martin, F. C. Collins, B. J. Hoffer, and G. A. Gerhardt. 1995. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363: 345-358.
11. Gash, D. M., Z. Zhang, A. Ovadia, W. A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, RA. Lapchak, F. C. Collins, B. J. Hoffer, and G. A. Gerhardt. 1996. Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 380: 252-255.
12. German, D. C., K. F. Manaye, P. K. Sonsalla, and B. A. Brooks. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann. N.Y. Acad. Sci. 648: 42-62.
13. Gillard, E. R., D. Q. Dang, and B. G. Stanley. 1993. Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Res. 628: 128-136.
14. Granholm, A. C., J. L. Mott, K. Bowenkamp, S. Eken, S. Henry, B. J. Hoffer, P. A. Lapchak, C. van Home, and G. A. Gerhardt. 1997. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-OHDA lesioned striatum. Exp. Brain Res., in press.
15. Hebert, M. A., C. G. van Home, B. J. Hoffer, and G. A. Gerhardt. 1996. Functional effects of GDNF in normal rat striatum: Presynaptic studies using in vivo electrochemistry and microdialysis. JPET 279: 1181-1190.
16. Hefti, F., T. L. Denton, B. Knusel, and P. A. Lapchak. 1994. Neurotrophic Factors: What are they and what are they doing? In Neurotrophic Factors (S. E. Loughlin and J. H. Fallon, Eds.), pp. 25-49. Academic Press, New York.
17. Henderson, C. E. 1996. Role of neurotrophic factors in neuronal development. Curr. Opin. Neurobiol. 6: 64-70.
18. Heumann, R. 1994. Neurotrophin signalling. Curr. Opin. Neurobiol. 4: 668-679.
19. Hoffer, B. J., A. Hoffman, and K. Bowenkamp. 1994. Glial cell line-derived neurotrophic factor reversed toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182: 107-111.
20. Hornykiewicz, O., and S. J. Fish. 1986. Biochemical pathophysiology in Parkinson's disease. Adv. Neurol. 45: 19-34.
21. Hou, J. G. G., L. F. H. Lin, and C. Mytilineou. 1996. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66: 74-82.
22. Hudson, J., A. C. Granholm, G. A. Gerhardt, M. A. Henry, A. Hoffman, P. Biddle, N. S. Leela, L. Mackerlova, J. D. Lile, F. Collins, and B. J. Hoffer. 1995. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36: 425-432.
23. Humpel, C., B. Hoffer, I. Stromberg, S. Bektesh, F. Collins, and L. Olson. 1994. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 59: 791-795.
24. 125I-glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci. Lett. 220: 187-190.
25. Kalivas, P. W., and J. Stewart. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16: 223-244.
26. Kearns, C. M., and D. M. Gash. 1995. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672: 101-111.
27. Kupsch, A., W. H. Oertel, C. D. Earl, and J. Sauter. 1995. Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease - Update February 1995. J. Neural Transm. 46: 193-207.
28. Kurlan, R., M. H. Kim, and D. M. Gash. 1991. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism. Movement Disorders 6: 111-118.
29. Langston, J. W., L. S. Forno, C. S. Rebert, and I. Irwin. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292: 390-394.
30. Lapchak, P. A., D. M. Araujo, and F. Hefti. 1992. Neurotrophins in the CNS. Rev. Neurosci. 3: 1-10.
31. Lapchak, P. A., S. S. Jiao, P. J. Miller, L. R. Williams, V. Cummins, G. Inouye, C. R. Matheson, and Q. Yan. 1996. Pharmacological characterization of glial cell line-derived neurotrophic factor: Implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tissue Res. 286: 179-189.
32. Lapchak, P. A., S. Jiao, F. Collins, and P. J. Miller. 1997. Glial cell line-derived neurotrophic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res., 747: 92-102.
33. Lapchak, P. A., P. J. Miller, F, Collins, and S. Jiao. 1997. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine lesioned rats: Comparison of intraventricular and intranigral delivery. Neuroscience in press.
34. Lapchak, P. A. 1996. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7: 165-176.
35. Lapchak, P. A., P. J. Miller, and S. Jiao. 1997. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience, 77: 745-52.
36. 125I]-GDNF in unlesioned and MPTP-lesioned rhesus monkey brain following an intraventricular injection. Submitted.
37. Leenders, K. L., E. P. Salmon, P. Tyrrell, D. Perani, D. J. Brooks, H. Sager, T. Jones, D. Marsden, and R. S. J. Franchowiak. 1993. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch. Neurol. 47: 1290-1298.
38. Lin, L-F., D. H. Doherty, J. D. Lile, S. Bektesh, and F. Collins. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
39. Lin, L-F., T. J. Zhangh, F. Collins, and L. G. Armes. 1994. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63: 758-768.
40. 3H]GBR 12935 binding to dopamine uptake sites: Subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur. J. Pharmacol. 156: 331-340.
41. Marsden, C. D., and J. D. Parkes. 1976. "On-off" effects in patients with Parkinson's disease. Lancet 1: 292-296.
42. Marsden, C. D., J. D. Parkes, and N. Quinn. 1982. Fluctuations of disability in Parkinson's disease - Clinical aspects. In Movement Disorders (C. D. Marsden and S. Fahn, Eds.), pp. 96-122. Butterworths Scientific, London.
43. Martin, D., G. Miller, N. Fischer, D. Dix, and T. Cullen. 1996. Glial cell line-derived neurotrophic factor: The lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur. J. Neurosci. 8: 1249-1255.
44. Miller, G., D. Martin, and T. Cullen. 1994. Central administration of GDNF causes augmentation of dopaminergic activity in vivo. Soc Neurosci. Abstr. 20: 1300.
45. Miyoshi, Y., Z. Zhang, A. Ovadia, P. A. Lapchak, F. Collins, D. C. Hilt, C. Lebel, R. Kryscio, and D. M. Gash. 1997. GDNF-levodopa interactions and reduction of side effects in Parkinsonian monkeys. Ann. Neurol., in press.
46. Mount, H. T. J., D. O. Dean, J. Alberch, C. F. Dreyfus, and I. B. Black. 1995. GDNF promotes the survival and morphologic differentiation of Purkinje cells. Proc. Natl. Acad. Sci. USA 92: 9092-9096.
47. Opacka-Juffry, J., S. Ashworth, S. P. Hume, D. Martin, Brooks, and S. B. Blunt. 1995. GDNF protects against 6-OHDA nigrostriatal lesions: In vivo study with microdialysis and PET. Neuroreport 7: 348-352.
48. Oppenheim, R. W. 1991. Cell death during development of the nervous system. Annu. Rev. Neurosci. 14: 453-501.
49. Pare, D., R. Curro'Dossi, and M. Steriade. 1990. Neuronal basis of the parkinsonian resting tremor: A hypothesis and its implications for treatment. Neuroscience 35: 217-226.
50. Penney, J. B. and A. B. Young. 1992. Movement disorders. In Principles of Drug Therapy in Neurology (M. V. Johnston, R. I. MacDonald, and A. B. Young, Eds.). F. A. Davis, Philadelphia.
51. Sauer, H., C. Rosenblad, and A. Bjorklund. 1995. Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral neurons following striatal 6-hydroxydopamine lesions. Proc. Natl. Acad. Sci. USA 92: 8935-8939.
52. Scharr, D. G., B. A. Sieber, C. F. Dreyfus, and I. Black. 1993. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol. 124: 368-371.
53. Schmidt-Kastner, R., A. Tomac, B. Hoffer, S. Bektesh, B. Rosenzweig, and L. Olson. 1994. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Mol. Brain Res. 26: 325-330.
54. Shults, C. W., T. Kimber, and D. Martin. 1996. Intrastriatal injections GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 7: 627-631.
55. Smith, R. D., Z. Zhang, R. Kurlan, M. McDermott, and D. M. Gash. 1993. Developing a stable bilateral model of Parkinsonism in rhesus monkey. Neuroscience 52: 7-16.
56. Snider, W. D., and E. M. Johnson. 1989. Neurotrophic molecules. Ann. Neurol. 26: 489-506.
57. Stromberg, I., L. Bjorklund, M. Johansson, A. Tomac, F. Collins, L. Olson, B. J. Hoffer, and C. Humpel. 1993. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 124: 401-412.
58. Suter-Crazzolara, C., and K. Unsicker. 1994. GDNF is expressed in two forms in many tissues outside the CNS. Neuroreport 5: 2486-2488.
59. Thoenen, H. 1991. The changing scene of neurotrophic factors. Trends Neurosci. 14: 165-170.
60. Tomac, A., J. Widenfalk, L. F. H. Lin, T. Kohno, T. Ebendal, B. J. Hoffer, and L. Olson. 1995. Retrograde axonal transport of GDNF in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. USA 92: 8274-8278.
61. Tomac, A., E. Lindqvist, L. F. H. Lin, S. O. Ogren, D. Young, B. J. Hoffer, and L. Olson. 1995. Protection and repair of nigrostriatal dopaminergic neurons by GDNF in vivo. Nature 373: 335-339.
62. Torack, R. M. and J. C. Morris. 1992. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J. Neural Transm. 4: 165-171.
63. Trupp, M., M. Ryden, H. Jornvall, H. Funakoshi, T. Timmusk, E. Arenas, and C. F. Ibanez. 1995. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J. Cell Biol. 130: 137-148.
64. Winkler, C., H. Sauer, C. S. Lee, and A. Bjorklund. 1996. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16: 7206-7215.
65. Zhang, Z., Y. Miyoshi, P. A. Lapchak, F. Collins, D. C. Hilt, C. Lebel, R. Kryscio, and D. M. Gash. 1997. Dose response to intraventricular GDNF administration in Parkinsonian monkeys. Submitted.